Novartis International AG is one of the multinational pharmaceutical companies which is headquartered in Basel, Switzerland. The company is engaged in producing products such as dietary fiber supplements, Benefiber and the popular anti-fungal formulation like Lamisil. Another pharmaceutical company which substantially produces various generic medications known as Sandoz Laboratories is also owned by Novartis. Novartis was constituted during 1996 following the amalgamation of Ciba-Geigy and Sandoz Laboratories both of which are well known Swiss companies with healthy histories. This amalgamation was considered as the biggest corporate unification in the history.   

The pharmaceutical division of Novartis International AG is acknowledged all over the world for the advanced medications provided by the company to the patients, doctors and different healthcare associations. Novartis has been developing and selling patented prescription medications for various significant health requirements. The most of the products of the company are focused on foremost therapeutic sectors such as: cardiovascular & metabolism, oncology & hematology, neuroscience, respiratory, infectious diseases, transplantation & immunology, ophthalmic, dermatology, gastrointestinal, urinary, arthritis and bones.

Novartis has also been awarded 15 new pharmaceutical product clearances since 2000 by the FDA for sales within United States which is more than any other pharmaceutical company would ever have. However, the present product range covers over 45 significantly sold products several of which heads in their relevant therapeutic sectors. According to the experts in the industry, Novartis is the leader as it is having the best combinations of organic developments, pipeline prospects and least patent-risk revelation among leading pharmaceutical companies.

The major product line of the company includes: Diovan, Exelon, Lamisil, Gleevec, Lotrel, Zometa, Neoral, Zelnorm, Benefiber and Clomicalm.